PMV Pharmaceuticals, Inc - PMVP Net Assets per Single Share

Graphic logo of PMV Pharmaceuticals, Inc. (PMVP)

High demand for targeted oncology drives significant R&D expenditures. The trend in book value per share demonstrates financial stability, with 1.33 representing the current metric. The success of PMV Pharmaceuticals (PMVP) relies on the precision selection of patients with the p53 mutation, while therapy safety is guaranteed by strict adherence to temperature controls during drug transportation.

PMVP: PMV Pharma Net Asset Value per Share 07/04/2022 - 10/28/2026

pmvpharma.com - analytical breakdowns and key metrics (PMVP)

- price and consensus price forecast:
Stock Quotes PMV Pharma|PMVP - Price Target Chart
- market capitalization data:
Market Value PMV Pharmaceuticals, Inc.|PMVP - Full Business Value
- book capitalization data:
Net Assets per Single Share PMV Pharmaceuticals|PMVP - Total Stockholders' Equity|Market Value to Book Value Ratio pmvpharma.com|PMVP - Total Business Assets
- debt and liquidity data:
Total Debt to Capital PMV Pharmaceuticals|PMVP - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity PMV Pharmaceuticals, Inc.|PMVP - Company Cumulative Debt|Debt to Book Capitalization Ratio PMV Pharmaceuticals, Inc.
Fundamental company valuation:PMVP - PMV Pharma
Flagship merchandise of PMV Pharmaceuticals, Inc.

For institutional investors, PMV Pharmaceuticals (PMVP) is an attractive defensive asset within the oncology therapy sector, where the absence of geopolitical risks in the US stabilizes fundamental value. By analyzing the book value per share, we assess net assets minus liabilities, which determines the real capital preservation threshold in the event of liquidation of PMV Pharmaceuticals and confirms the startup's financial stability.

Competitor analysis for PMV Pharmaceuticals

GMAB - Accounting Value per Share|EXEL: Net Assets per Single Share|Net Assets per Single Share Nuvalent, Inc. (NUVL)|KYMR (kymeratx.com) - Share Book Value|Net Assets per Single Share IDYA (IDEAYA Biosciences, Inc.)|Net Asset Value per Share ELVN|Net Assets per Single Share ORIC Pharma ORIC|Equity per Share Relay Corp (RLAY)|Nurix Therapeutics - Book Value per Share|tyra.bio - Accounting Value per Share|VSTM (Verastem) - Net Assets per Single Share|GLUE: Net Asset Value per Share|Cullinan Therapeutics Inc (CGEM) - Net Assets per Single Share|IMRX (Immuneering Corp.) - Net Assets per Single Share|Net Assets per Single Share CCCC (C4 Therapeutics, Inc.)|Net Asset Value per Share blackdiamondtherapeutics.com|RPTX: Book Value per Share|Book Value of One Share karyopharm.com KPTI|PPCB: Accounting Value per Share|BGMS - Net Asset Value per Share|Accounting Value per Share Aadi Bio (AADI)|Aileron Therapeutics (ALRN) - Accounting Value of a Share|BPMC - Accounting Value per Share|GlycoMimetics (GLYC) - Book Price of a Share|SWTX (SpringWorks) - Book Value per Share